RayKnowChina Research Map
Shortlist

Not yet recruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06996093, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Early-stage breast cancer, with postoperative pathology confirming invasive carcinoma, HR-positive and HER2-negative (In this study, HR-positive is defined as: ER-positive by IHC with >10% tumor cells staining positive; HER2-negative defined as HER2 0-1+ by IHC or HER2++ with negative FISH result, without amplification);

    Inclusion criterion 3

    Postoperative pathological stage pT2N0M0 and:

    Inclusion criterion 4

  3. Men and women of childbearing potential unwilling to use contraception during treatment and for 8 weeks after treatment completion;

    Exclusion criterion 11

  4. ECOG performance status 0-1;

    Inclusion criterion 2

  5. Clinical or imaging suspicion of malignancy in the contralateral breast requiring biopsy (unless ruled out);

    Exclusion criterion 3

    Use of tamoxifen, raloxifene, or aromatase inhibitors (AIs) for breast cancer risk reduction ("chemoprevention") and/or osteoporosis treatment within the past 2 years;

    Exclusion criterion 5

    History of other malignancies within the past 5 years (except basal cell carcinoma of the skin or carcinoma in situ of the cervix), including contralateral breast cancer;

    Exclusion criterion 6

  6. Pregnant or lactating women;

    Exclusion criterion 12

    Positive pregnancy test before study drug administration (for women of childbearing potential);

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06996093, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Females and males aged 18-70 years;
  • ECOG performance status 0-1;
  • Early-stage breast cancer, with postoperative pathology confirming invasive carcinoma, HR-positive and HER2-negative (In this study, HR-positive is defined as: ER-positive by IHC with >10% tumor cells staining positive; HER2-negative defined as HER2 0-1+ by IHC or HER2++ with negative FISH result, without amplification);
  • Postoperative pathological stage pT2N0M0 and:

Histological grade 3, or Histological grade 2 with Ki67 ≥ 20% or high-risk multigene assay results;

  • No prior neoadjuvant therapy received;
  • Good postoperative recovery, with randomization occurring no more than 8 weeks after surgery;
  • Normal function of major organs, meeting the following criteria:

Hematological tests must meet: HB ≥90 g/L (no transfusion within 14 days); ANC ≥1.5×10⁹/L; PLT ≥100×10⁹/L; Biochemical tests must meet: TBIL ≤1.5×ULN (upper limit of normal); ALT and AST ≤3×ULN; serum Cr ≤1.5×ULN;

  • Contraception required for male participants and women of childbearing potential during treatment;
  • Participants voluntarily enroll in the study, sign informed consent, demonstrate good compliance, and cooperate with follow-up.

Exclusion Criteria:

  • Bilateral breast cancer or carcinoma in situ (DCIS/LCIS);
  • Metastasis at any site;
  • Clinical or imaging suspicion of malignancy in the contralateral breast requiring biopsy (unless ruled out);
  • Prior neoadjuvant therapy, including chemotherapy, radiotherapy, or endocrine therapy;
  • Use of tamoxifen, raloxifene, or aromatase inhibitors (AIs) for breast cancer risk reduction ("chemoprevention") and/or osteoporosis treatment within the past 2 years;
  • History of other malignancies within the past 5 years (except basal cell carcinoma of the skin or carcinoma in situ of the cervix), including contralateral breast cancer;
  • Concurrent participation in another clinical trial;
  • Severe systemic diseases and/or uncontrolled infections that preclude study participation;
  • Severe cardiovascular or cerebrovascular events within 6 months before randomization (e.g., unstable angina, chronic heart failure, uncontrolled hypertension >150/90 mmHg, myocardial infarction, or stroke);
  • Known hypersensitivity to the study drugs;
  • Men and women of childbearing potential unwilling to use contraception during treatment and for 8 weeks after treatment completion;
  • Pregnant or lactating women;
  • Positive pregnancy test before study drug administration (for women of childbearing potential);
  • Psychiatric disorders, cognitive impairment, or inability to comprehend the trial protocol, adverse effects, or comply with study procedures and follow-up (requires systematic evaluation before enrollment);
  • Individuals lacking personal freedom or legal capacity for independent civil conduct.

Quoted from ClinicalTrials.gov, NCT06996093, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06996093, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06996093